Harrow full-year 2023 revenue $130.2M (+47% YoY), GAAP net loss widens to $24.4M; adj EBITDA $28.1M

HARROW, INC.

FY2023 revenue $130.2M, up 47% YoY; GAAP net loss $24.4M (vs $14.1M loss in 2022).
Adjusted EBITDA $28.1M, +116% YoY; cash from ops $3.8M full-year, $8.7M in Q4.
IHEEZO Q4 reorder rate 83%; Q1 2024 sales impacted by Change Healthcare cyberattack; CMS added J-code to ASP file.
VEVYE launch exceeding expectations; 70% refill rate; over 40M covered lives including TriCare and Aetna.
TRIESENCE first PPQ batch scheduled for April 15; NDA transferred; price set at $944/unit; targeting 90K units inventory.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HARROW, INC. reported the year and quarter ended December 31, 2023 results: revenue $130,193,000, net income $(24,411,000), EPS $(0.75).

Period: the year and quarter ended December 31, 2023
Revenue: $130,193,000
Net income: $(24,411,000)
EPS: $(0.75)
Result: reported results

Exact text from the filing

Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Harrow Announces Fourth Quarter and Year-End 2023 Financial Results Full-Year 2023 Highlights: ● Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. ● GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. ● Adjusted EBITDA of $28.1

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

HARROW, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-010520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.